Wikipedia -WSS

Wikipedia

author：fashion 2025-09-29 20:00:26 - browse：426

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： STAT Readout: Today's biotech news includes Sana and Amylyx

focus

WSS

Why scientists need input from humanists on sensitive research

Why depression after traumatic brain injury is distinct

How doctors and nurses shape Google's AI

How clinical AI models' predictive power can degrade over time

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

European regulators consider appeal over Amylyx ALS drug

entertainment

Wikipedia

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Eight reasons why you should get an updated Covid vaccine

Virginia high school admissions case could be legal follow

What the Wegovy shortage looks like for doctors — and for patients

Guidelines to prevent youth baseball injuries need more muscle

What the Wegovy shortage looks like for doctors — and for patients

Medical records are filled with copy

What the Wegovy shortage looks like for doctors — and for patients

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: Merger Mondays, Ozempic panic

explore

Medicare coverage of Wegovy, once blocked, now looks possible

President Biden's budget: Here's what you might have missed

Nick Jonas talks about managing diabetes along with his career

Pushing for an NIH office for post

How many hemophilia patients actually want gene therapy?

Humana CEO Bruce Broussard to step down in 2024

focus

hotspot

focus

hotspot